BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook

BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress • Continued to advance monotherapy and combination cohorts for all clinical programs • Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, in

AbbVie (NYSE:ABBV) reported that its migraine drug Qulipta met the main goal in a late-stage study, showing a 0.8-day reduction in migraine days for menstrual-related migraines. The results could expand Qulipta's use and support an additional indication, strengthening AbbVie's migraine portfolio. However, the modest efficacy and market competition may limit its commercial impact.

Pinterest (PINS) shares rose 1.8% after announcing an AI infrastructure layer built with NVIDIA (NVDA) using Blackwell GPUs. The system supports multimodal AI products, improving response times and latency. Pinterest processes over 80 billion monthly searches with this technology. The collaboration spans nearly five years and 14,000 NVIDIA GPUs.

Bionano Genomics (BNGO) reported that three studies showed its optical genome mapping (OGM) technology identified high-risk genomic alterations in blood cancers, often missed by standard methods. OGM detected significant variants in 15.9% of MDS cases and 46% of cytogenetically normal AML samples, impacting survival rates. The studies suggest OGM could improve risk stratification and treatment planning. BNGO shares are up 2.05% at $1.24.

Radiopharm Theranostics (RADX) announced positive interim data from its Phase 2b trial of RAD101, a PET imaging agent for brain metastases, was selected for a late-breaking presentation at the SNO26 meeting. The data showed 93% concordance with MRI and 86% sensitivity. RAD101 has FDA Fast Track designation. The company plans a Phase 3 trial and expects to meet with the FDA in October 2026. RADX stock is up 0.17% at $1.98.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. The study showed significant reduction in HAM-A scores with a 5.1-point placebo-adjusted improvement. The company plans to submit a New Drug Application in early 2027. DFTX stock rose 3.07% to $38.89 on Friday and is up 13.40% in pre-market trading.